Lin Zhu et al. tried to find the predictive biomarkers of immunotherapy for ES-SCLC, such as PD-L1, tumor mutation burden (TMB), molecular subtypes, and gene expression; at present, the molecular subtypes defined from transcription factors may have some guiding significance, which still needs to be confirmed by prospective clinical studies [35]. This evidence concerns the gene CD274 and neoplasm.